Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 345 | 28% |
| 2020 | 5 | 244 | 30% |
| 2021 | 5 | 375 | 32% |
| 2022 | 6 | 253 | 35% |
| 2023 | 7 | 289 | 38% |
| 2024 | 6 | 233 | 39% |
| 2025 from claims | – | 247 200–291 | 40% |
| 2026 forecast | – | 255 200–320 | 39% |
| 2027 forecast | – | 259 192–342 | 40% |
| 2028 forecast | – | 263 186–363 | 40% |
| 2029 forecast | – | 267 182–383 | 40% |
| 2030 forecast | – | 271 178–403 | 40% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Massachusetts; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 36% inpatient hospital, 64% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 4 | 485−4.3%/yr | −4.3%/yr | 0.3 | 0% | 620 in 2030+4.1%/yr |
| New York | 8 | 452−3.8%/yr | −3.8%/yr | 0.2 | 0% | 480 in 2030+0.9%/yr |
| New Jersey | 4 | 206+7.7%/yr | +7.7%/yr | 0.2 | 0% | 280 in 2030+5.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 13 | 456+8%/yr | +8%/yr | 0.50.9× | 0% | 820 in 2030+10%/yr |
| Stroke thrombectomy | 15 | 351+2.1%/yr | +2.1%/yr | 0.40.8× | 0% | 410 in 2030+2.8%/yr |
| CSF shunts | 5 | 193−8.4%/yr | −8.4%/yr | 0.21.0× | 0% | 220 in 2030+1.9%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with Pennsylvania
Neuropace leads with 35% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 6 companies reported engagement with Massachusetts’s surgeons worth $98K in consulting, speaking, meals and travel tied to these products, about $16K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.